Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial

Blood (2024) 144 (Supplement 1): 1053.

https://doi.org/10.1182/blood-2024-208486

Published: 2024

Journal Articles

Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec

Laurent Frenzel, Kaan Kavakli, Andrew D. Leavitt, Ali Bülent Antmen, Davide Matino, Margareth Ozelo, Hazza Alzahrani, Barbara A. Konkle, Maria de los Angeles Resa, Annie F. Fang, Jasmine Healy, Delphine Agathon, Francesca Biondo, Frank Plonski

Blood (2024) 144 (Supplement 1): 3575.

https://doi.org/10.1182/blood-2024-193368

Published: 2024

Journal Articles

Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety

Ben Samelson-Jones, Laurent Frenzel, Kaan Kavakli, Adam Cuker, Jerome M. Teitel, Pengling Sun, Lisa J Wilcox, Francesca Biondo, Benjamin Hutter, John McKay, Delphine Agathon, Frank Plonski

Blood (2024) 144 (Supplement 1): 3577.

https://doi.org/10.1182/blood-2024-193453

Published: 2024

Journal Articles

Characterizing a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec from the Phase 3 Benegene-2 Study Who Returned to Factor IX Prophylaxis

Laurent Frenzel, Kaan Kavakli, Robert Klamroth, Shyh-Shin Chiou, Amy D. Shapiro, Pengling Sun, Joanne Fuiman, John McKay, Annie F. Fang, Francesca Biondo, Frank Plonski, Jeremy Rupon

Blood (2023) 142 (Supplement 1): 2257.

https://doi.org/10.1182/blood-2023-181223

Published: 2023

Journal Articles

Marstacimab, an Anti-Tissue Factor Pathway Inhibitor, in Participants with Hemophilia Α or B, with and without Inhibitors: An Integrated Analysis of Safety

Suchitra Acharya, Davide Matino, Johnny Mahlangu, Carrie Turich Taylor, Eunhee Hwang, Tina Hinnershitz, Eugeny Mefyod, Andrew Palladino, Francesca Biondo, Travis Gould, John Teeter

Blood (2023) 142 (Supplement 1): 3980.

https://doi.org/10.1182/blood-2023-174682

Published: 2023

Journal Articles

Clinical Features of Idiopathic Erythrocytosis Compared to Polycythemia Vera JAK-2 V617F Positive and Negative Patients

Roberto Latagliata, Agostino Tafuri, Antonio Spadea, Antonietta Ferretti, Daniela Diverio, Massimo Breccia, Mariella D'Andrea, Alessandro Andriani, Marco Montanaro, Michele Cedrone, Enrico Montefusco, Angela Rago, M.D., Odoardo Maria Olimpieri, Antonino Bagnato, MD, Francesca Biondo, Federico Vozella, Maria Cantonetti, MD, Maria Concetta Petti, MD, Giuliana Alimena

Blood (2011) 118 (21): 5172.

https://doi.org/10.1182/blood.V118.21.5172.5172

Published: 2011

Journal Articles

Decisional Flow with a Score System To Start Platelet-Lowering Treatment in Patients with Essential Thrombocythemia (ET): Long-Term Results.

Roberto Latagliata, MD, Angela Rago, MD, Antonio Spadea, MD, Cristina Santoro, MD, Ida Carmosino, MD, Massimo Breccia, MD, Laura Napoleone, MD, Angelo Fama, MD, Francesca Biondo, MD, Paola Volpicelli, MD, Maria Concetta Petti, PhD, Giuliana Alimena, PhD, Maria Gabriella Mazzucconi, PhD

Blood (2007) 110 (11): 4636.

https://doi.org/10.1182/blood.V110.11.4636.4636

Published: 2007

Journal Articles

Rituximab in Refractory Idiopathic Thrombocytopenic Purpura (ITP).

Cristina Santoro, MD, Francesca Biondo, MD, Gioia De Angelis, MD, Mariastefania De Propris, BD, Annalisa De Vellis, MD, Anna Guarini, BD, Luigi Malandruccolo, MD, Angela Rago, MD, Robert Foa, MD, Mariagabriella Mazzucconi, MD

Blood (2006) 108 (11): 3979.

https://doi.org/10.1182/blood.V108.11.3979.3979

Published: 2006

Journal Articles

Association of Hydroxyurea to Imatinib Is Effective in Patients with Chronic Myelogenous Leukemia Resistant to Imatinib Alone.

Roberto Latagliata, MD, Massimo Breccia, MD, Ida Carmosino, MD, Chiara Sarlo, MD, Rosa De Cuia, MD, Marco Mancini, MD, Francesca Biondo, MD, Eleonora Russo, MD, Annalisa De Vellis, MD, Daniela Diverio, MD, Franco Mandelli, PhD, Giuliana Alimena, PhD

Blood (2004) 104 (11): 4693.

https://doi.org/10.1182/blood.V104.11.4693.4693

Published: 2004

NARROW

Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial

Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec

Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety

Characterizing a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec from the Phase 3 Benegene-2 Study Who Returned to Factor IX Prophylaxis

Marstacimab, an Anti-Tissue Factor Pathway Inhibitor, in Participants with Hemophilia Α or B, with and without Inhibitors: An Integrated Analysis of Safety

Clinical Features of Idiopathic Erythrocytosis Compared to Polycythemia Vera JAK-2 V617F Positive and Negative Patients

Decisional Flow with a Score System To Start Platelet-Lowering Treatment in Patients with Essential Thrombocythemia (ET): Long-Term Results.

Rituximab in Refractory Idiopathic Thrombocytopenic Purpura (ITP).

Association of Hydroxyurea to Imatinib Is Effective in Patients with Chronic Myelogenous Leukemia Resistant to Imatinib Alone.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only